Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2015 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
December 17, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
November 11, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics Reports Third Quarter 2014 Results

CAMBRIDGE, Mass., Nov. 11, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
November 10, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus

SAGE-547 Met Primary and Secondary Efficacy and Safety Endpoint Targets Overall Response Rate of 73 Percent Reported with No Drug-Related SAEs CAMBRIDGE, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE)...
November 07, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics Announces Six Scientific Presentations at Neuroscience 2014, the Society for Neuroscience's 44th Annual Meeting

CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
November 05, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE to Present at Credit Suisse 23rd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
November 03, 2014 06:30 ET | Source: SAGE Therapeutics

First Evaluation of SAGE-547 to Treat Super-Refractory Status Epilepticus in Children Published in Annals of Neurology

CAMBRIDGE, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced that SAGE-547, an allosteric modulator of GABAA receptors, was used to treat super-refractory status...
October 23, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor

CAMBRIDGE, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced dose initiation of the first patient in a single-center Phase 2a clinical trial of SAGE-547, an...
September 25, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics to Participate in the 2014 Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass., Sept. 25, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
September 16, 2014 06:30 ET | Source: SAGE Therapeutics

SAGE Therapeutics Appoints Michael F. Cola to the Company's Board of Directors

CAMBRIDGE, Mass., Sept. 16, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...